Journal article

Group A streptococcal vaccines: Paving a path for accelerated development

James B Dale, Vincent A Fischetti, Jonathan R Carapetis, Andrew C Steer, Samba Sow, Rajesh Kumar, Bongani M Mayosi, Fran A Rubin, Kim Mulholland, Joachim Maria Hombach, Florian Schoedel, Ana Maria Henao-Restrepo

VACCINE | ELSEVIER SCI LTD | Published : 2013

Abstract

Group A streptococci (GAS) are important causes of morbidity and mortality worldwide. These organisms cause a wide spectrum of disease, ranging from uncomplicated sore throat to invasive, life-threatening infections, as well as immune complications such as acute rheumatic fever (ARF), rheumatic heart disease (RHD) and acute post-streptococcal glomerulonephritis (APSGN). Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades. Several vaccine candidates against GAS infection are in various stages of pre-clinical and clinical development, including M protein-based vaccines (N-terminal vaccine candidates and M protein conserved regio..

View full abstract